Adinazolam sustained-release treatment of panic disorder: A double-blind study

J. R T Davidson, B. Beitman, J. H. Greist, Richard J Maddock, C. P. Lewis, A. Q. Sheridan, Cameron S Carter, K. R. Krishnan, M. R. Liebowitz, D. G. Haack

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Two hundred six outpatients with panic disorder and agoraphobia were randomly assigned to receive 4 weeks of treatment with placebo or sustained- release adinazolam under double-blind conditions. Eighty-eight percent of patients receiving drug and 85% of patients receiving placebo remained in the study at week 4. This report describes the 'intent-to-treat' analysis of 202 patients who made at least one follow-up visit after randomization at baseline. On the basis of the Clinical Global Impressions-Improvement Scale, 69.7% of the adinazolam-treated patients were much or very much improved compared with 39.6% of the placebo-treated patients at week 4 or end-point (p = 0.0001). At week 4, panic attacks were completely blocked in 57.1% of adinazolam-treated patients and in 39.2% of the placebo-treated patients (p = 0.009). Adinazolam sustained-release treatment was statistically more effective than placebo treatment on measures of global improvement, number of panic attacks, SCL-90 phobia severity, main phobia severity, and anticipatory and general anxiety. No drug-placebo differences were found for overall self- rated phobia severity, unexpected or situational panic attacks, or for work, family, or social disability.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalJournal of Clinical Psychopharmacology
Volume14
Issue number4
StatePublished - 1994

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Adinazolam sustained-release treatment of panic disorder: A double-blind study'. Together they form a unique fingerprint.

Cite this